Evidence map›Paper›PMID 34468818›Full record

ReviewDer Pathologe2021

[Oncocytic tumours of the kidney-new differential diagnoses].

I Polifka, R Ohashi, H Moch

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Pathologe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

I PolifkaInstitut für Pathologie, Universitätsklinikum Erlangen, Krankenhausstraße 8-10, 91054, Erlangen, Deutschland. iris.polifka@uk-erlangen.de.
R OhashiHistopathology Core Facility, Faculty of Medicine, Niigata University, 1-757 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan.
H MochDepartment für Pathologie und Molekularpathologie, Universitätsklinik Zürich, Schmelzbergstraße 12, 8091, Zürich, Schweiz.
Niigata University · JPUniversitätsklinikum Erlangen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent developments in differential diagnosis have led to new knowledge about oncocytic renal neoplasms.

objectivesOverview of differential diagnosis of oncocytic tumours. MATERIALS AND

methodsWe performed a literature search on oncocytic renal tumours and mapped known tumour types. Possible differential diagnoses are discussed.

resultsBesides the tumour types already acknowledged by the 2016 WHO classification, there is new evidence regarding the group of hard-to-classify oncocytic neoplasms. Findings point to immunohistochemical and molecular characteristics that may lead to the establishment of new entities in the future. In addition, important differential diagnosis can now be identified, facilitating specific therapies for oncocytic renal tumours.

conclusionA correct diagnosis of oncocytic renal tumours not only improves prognostic assessment (and, if necessary, specific therapies) but is also clinically relevant regarding a possible association with hereditary tumour syndromes.

Indexed as

Adenoma, OxyphilicCarcinoma, Renal CellKidney NeoplasmsDiagnosis, DifferentialHumansImmunohistochemistryChromophobe renal cell carcinomaESCMTOROncocytomaSDH

Identifiers

PMID34468818
OpenAlexW3198628730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.